glucagon receptor retatrutide Research Guide: What the Phase 2 Trial Data Reported (2026) retatrutide triple agonist glp-1 gip

She endorsed nausea, bloating, and constipation

Looking Ahead GLP-1 drugs have revolutionized treatment for obesity, but recent regulatory activity is a reminder that existing rules apply even when the innovation is revolutionary

Retatrutide is a triple agonist that adds glucagon-receptor (GCGR) activity to the GLP-1 and GIP activity that tirzepatide already has

For our full lineup ranked by price, see our guide to the cheapest tirzepatide providers

Frequently asked questions Does insurance cover weight loss programs

A legitimate online clinic will have access to both and will guide you through this decision, not just let you pick one from a dropdown menu